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Mutations in retinol dehydrogenase 12 (RDH12) cause severe retinal degeneration. However, some
of the disease-associated RDH12 mutants retain signiﬁcant catalytic activity, indicating the exis-
tence of additional pathophysiological mechanisms. This study demonstrates that the catalytically
active T49M and I51N mutants undergo accelerated degradation, which results in their reduced cel-
lular levels. Inhibition of proteasome leads to signiﬁcant accumulation of ubiquitylated T49M and
I51N. Furthermore, the degree of ubiquitylation strongly correlates with the half-lives of the pro-
teins. These results suggest that the accelerated degradation of RDH12 mutants by the ubiquitin-
proteasome system contributes to the pathophysiology and phenotypic variability associated with
mutations in the RDH12 gene.
Structured summary:
MINT-7383581, MINT-7383598: RDH12 (uniprotkb:Q96NR8) physically interacts (MI:0915) with ubiquitin
(uniprotkb:P62988) by anti tag coimmunoprecipitation (MI:0007)
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Retinol dehydrogenase 12 (RDH12) has become the focus of
numerous investigations since mutations in RDH12 gene have been
genetically linked to the severe early-onset autosomal recessive
retinal dystrophy (arRD) [1,2] and Leber congenital amaurosis
(LCA) [3,4]. Most recently, a heterozygous mutation in RDH12
has been associated with autosomal dominant retinitis pigmentosa
[5]. Biochemical characterization of RDH12 properties suggests
that this enzyme functions as an NADP+-dependent oxidoreductase
that reduces all-trans-retinaldehyde to all-trans-retinol in photore-
ceptor inner segments [6–8]. All-trans-retinaldehyde is a natural
intermediate of the visual cycle and is produced in photoreceptor
outer segments as a result of photoisomerization of 11-cis-retinal-
dehyde covalently bound to rod and cone opsins [9]. As a highly
efﬁcient all-trans-retinaldehyde reductase [8], RDH12 is believed
to protect photoreceptors from toxic excess of retinaldehyde,
which diffuses into the inner segments of photoreceptors from illu-
minated rhodopsin [7,10].chemical Societies. Published by E
eme agglutinin
ili).At least 33 disease-associated mutations of RDH12 have been
identiﬁed to date [1–5]. These include truncations (stop codons),
frameshift mutations, and missense mutations. The phenotype of
RDH12-associated severe and early-onset retinal dystrophy is not
homogeneous [11], suggesting that the position and nature of the
mutations inﬂuence the pathologic expression of this disease.
Interestingly, some of the disease-causing RDH12 mutants (I51N
and T49M) retain signiﬁcant catalytic activity in vitro, exhibiting
the Vmax values that are similar (I51N) or higher (T49M) than that
of wild-type RDH12 [7]. These observations suggest that other fac-
tors may contribute to pathology associated with mutations in
RDH12. To obtain further insight into the properties of RDH12
mutants, we investigated the turnover rates of the catalytically
active T49M and I51N variants and identiﬁed the major pathways
responsible for their elimination.
2. Materials and methods
2.1. Materials
Lactacystin and calpastatin were from Calbiochem (EMD Chem-
icals Inc. Gibbstown, NJ). N-carbobenzoxyl-L-leucinyl-L-leucinyl-L-
leucinal (MG132), pepstatin A, leupeptin, chloroquine, and NH4Cl
were all from Sigma Aldrich Co. (St. Louis, MO).lsevier B.V. All rights reserved.
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Fig. 1. Turnover rates of RDH12 variants. (A) Pulse-chase analysis of RDH12 was
carried out for the indicated times (h). (B) The results from three independent
pulse-chase experiments were quantiﬁed by ImageQuant version 5.0 (Molecular
Dynamics, Piscataway, NJ). Wild-type (h); T49M (d); I51N (D). Data are
means ± S.D., n = 3. Inset, y axis is shown in logarithmic scale.
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tagged RDH12 variants
Expression vectors for HA-tagged RDH12 were prepared by
PCR-amplifying the corresponding cDNAs in pIRES vector [7]
using primers 50-TTGGAATTCATGCTGGTCACCTTGGGACTGC-30
and 50-CGCCTCGAGCTCCCACCGGATTCCTAGAAG-30 (EcoRI and
XhoI restriction sites underlined), and cloning the PCR product
after digestion with EcoRI and XhoI endonucleases into the
respective sites of pIRES-hrGFP-2a plasmid (Stratagene, La Jolla,
CA) in frame with the C-terminal HA tag.
2.3. Pulse-chase analysis
HEK293 cells were transfected with expression vectors for HA-
tagged wild-type or mutant RDH12. Twenty-four hours after trans-
fection, the medium was replaced by Dulbecco0s modiﬁed Eagle0s
medium (DMEM) lacking methionine/cysteine (Sigma–Aldrich).
After 30-min incubation, the cells were pulsed with methionine/
cysteine-free medium supplemented with 200 lCi of [35S] methio-
nine/cysteine (MP Biomedicals Inc., Irvine, CA) for 1 h and chased
in complete DMEM. At the indicated times, the cells were har-
vested and lysed in buffer containing 100 mM Tris, pH 7.4,
150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 0.5% NP-40, 1% Triton X-
100, 1 mM dithiothreitol (DTT) and protease inhibitors: 2 lg/ml
aprotinin, 2 lg/ml leupeptin, 1 lg/ml pepstatin A, 5 mM PMSF,
0.1 mM EDTA, and 5 mM benzamidine. For immunoprecipitation,
HA antibodies were cross-linked with immobilized protein A
(Pierce, Rockford, IL). The beads with cross-linked HA antibodies
were incubated with cell lysates at 4 C on a rotator overnight.
Immunoprecipitates were washed four times with the cell lysis
buffer. The proteins were eluted by the addition of an equal vol-
ume of 2X SDS–PAGE sample buffer and separated in 12% SDS–
PAGE. The bands were visualized by exposure to X-ray ﬁlm.
2.4. Treatment of cells with inhibitors of proteases
HEK293 cells were transfected with RDH12 expression con-
structs in pIRESneo vector as described before [7] and 24-h later
incubated with various protease inhibitors for 20 h; with ﬁxed con-
centration of lactacystin (5 lM) for 0–24 h; or with varied concen-
trations of lactacystin (0–20 lM) for 20 h.
2.5. Western blot analysis
Samples of cell lysates were subjected to 12% SDS–PAGE and
transferred to Hybond-P-membrane (Amersham Biosciences, Pis-
cataway, NJ). The membrane was incubated with either RDH12
rabbit polyclonal antiserum [7] at a 1:10 000 dilution, HA mono-
clonal antibodies at a 1:50 dilution, or MYC polyclonal antibodies
(Santa Cruz Biotechnology, Santa Cruz, CA) at a 1:1000 dilution.
b-Actin monoclonal antibodies (Sigma–Aldrich) were used at a
1:5000 dilution. The protein bands were visualized using chemilu-
minescent substrate (Pierce) after incubation with goat anti-rabbit
or anti-mouse antibodies conjugated to horseradish peroxidase (at
a 1:10 000 dilution).
2.6. Ubiquitylation assay
HEK293 cells were co-transfected with expression constructs
encoding HA-tagged wild-type or mutant RDH12 in pIRES-hrGFP-
2a vector and MYC-tagged ubiquitin expression plasmid, a kind gift
from Dr. Fang-Tsyr Lin (University of Alabama at Birmingham).
Twenty-four hours after transfection, the cells were incubated with
10 lM MG132 for 20 h, and then lysed as described above. Cell ly-
sates (500 lg) were incubated with Protein A beads cross-linked toHA antibody at 4 C overnight with shaking. Beads were collected
by centrifugation and washed four times with cell lysis buffer.
The bound proteins were eluted with SDS–PAGE sample buffer
and subjected to Western blot analysis using MYC polyclonal anti-
bodies in order to detect the ubiquitin-RDH12 conjugates.
3. Results
3.1. RDH12 variants have different half-lives
To determine the half-lives of RDH12 variants, we employed
pulse-chase analysis. Since RDH12 is not known to be expressed
endogenously in any of the available cell lines, these experiments
were conducted in HEK293 transiently transfected with expression
constructs for RDH12 as described previously [7]. Cells expressing
individual HA-taggedmutants were pulse labeled with [35S] methi-
onine/cysteine and then chased with methionine/cysteine contain-
ing medium. At the times indicated, cells were lysed and
immunoprecipitated using HA antibodies. The pulled-down radio-
labeled proteins were separated by denaturing gel electrophoresis
and visualized by ﬂuorography. As shown in Fig. 1A, the degrada-
tion rates of individual proteins were markedly different. Wild-
type RDH12 was the most stable protein, with a half-life of
7.7 ± 0.6 h. T49M variant exhibited a faster turnover rate with a
half-life of 4.6 ± 0.6 h, whereas I51N protein was the least stable
protein with a half-life of 1.8 ± 0.2 h (Fig. 1B, note the shorter time
scale for I51N). These half-lives were consistent with the amounts
of RDH12 variants observed in the cells (Fig. 2A) and revealed that
the differences in the steady-state levels of RDH12 variants were
determined primarily by the rates of their degradation.
3.2. Lysosomes have a minor role in degradation of RDH12
To identify the pathway responsible for degradation of T49M
and I51N proteins, we employed inhibitors targeting speciﬁc
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Fig. 2. Effects of calpain and lysosomal inhibitors on RDH12 degradation. HEK293
cells expressing wild-type (WT) or mutant RDH12 were incubated for 20 h in the
presence of indicated protease inhibitors. RDH12 in cell lysates (50 lg) was
detected using RDH12 antiserum. (A) Treatment with calpastatin (5 lM). (B)
Treatment with lysosomal inhibitors: chloroquine (100 lM), pepstatin A (100 lM),
leupeptin (50 lM), or NH4Cl (20 mM). The results are representative of three
independent experiments. Immunostaining for b-actin served as a control for
protein loading.
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Fig. 3. Effects of proteasomal inhibitors MG132 and lactacystin on RDH12
degradation. (A) HEK293 cells expressing wild-type or mutant RDH12 were
incubated for 20 h in the presence of MG132 (20 lM) or lactacystin (20 lM). Cell
lysates (50 lg) were immunoblotted using RDH12 antiserum. HEK293 cells
expressing I51N were incubated for 20 h in the presence of various concentrations
of lactacystin (B), or in the presence of 5 lM lactacystin for various times (C). I51N
protein in cell lysate (50 lg) was detected using RDH12 antiserum. The results are
representative of three independent experiments.
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in lysosomes or cytosol. Calpains, or calcium-dependent cysteine
proteases, constitute the major cytosolic proteolytic system that
degrades the plasma membrane and cytoskeletal proteins and sev-
eral membrane-associated enzymes [12]. Therefore, we tested the
effect of calpain inhibitor, calpastatin, on degradation of RDH12.
As shown in Fig. 2A, treatment of cells with calpastatin did not in-
crease the steady-state levels of the mutant proteins or wild-type
RDH12, indicating that calpainwas not involved in RDH12 degrada-
tion. Similarly, there was no signiﬁcant increase in RDH12 protein
levels after treatment of the cells with the inhibitor of aspartate
proteases pepstatin A or lysosomal protease inhibitor leupeptin.
However, a small but reproducible increase in both wild-type and
mutant RDH12 proteins was detected in the presence of lysosomal
acidiﬁcation inhibitors chloroquine and NH4Cl (Fig. 2B). The in-
crease in protein was especially pronounced for the T49M mutant,
suggesting that the lysosomal contribution may vary for individual
RDH12 variants expressed in HEK293 cells.
3.3. RDH12 is degraded primarily by the proteasome
The proteasome degrades short-lived cytosolic and nuclear pro-
teins, but recent evidence indicates that the proteasome also plays
a critical role in elimination of misfolded membrane-bound pro-
teins associated with endoplasmic reticulum [13]. To determine
the role of proteasome in degradation of RDH12, we employed
the commonly used proteasomal inhibitors MG132 and lactacystin.
Treatment of the cells with either MG132 or lactacystin resulted in
signiﬁcant accumulation of T49M and I51N mutant proteins,increasing their steady-state levels to those of the wild-type pro-
tein (Fig. 3A). Interestingly, the amount of wild-type RDH12 also
increased noticeably. This suggested that the proteasome has a
central role in degradation of both native and mutant RDH12
polypeptides.
To obtain further proof of proteasome involvement, we exam-
ined the time- and dose-dependence of lactacystin effect on the le-
vel of I51N, which exhibited the shortest half-life. The amount of
I51N observed in the cells after the treatment increased with
increasing concentrations of lactacystin (Fig. 3B). The protective ef-
fect of lactacystin was especially obvious after prolonged incuba-
tions. There was a greater difference in the levels of I51N
between treated and untreated cells after 24 h than after 6 h of
incubation (Fig. 3C). These observations provided further evidence
for the role of proteasome in RDH12 degradation.
3.4. Mutant RDH12 is targeted for proteasomal degradation by the
ubiquitin system
To determine whether the proteasomal degradation of RDH12
occurs through the ubiquitin-linked system, we employed the
ubiquitylation assay. HEK293 cells were co-transfected with
expression vectors encoding HA-tagged wild-type or mutant
RDH12 and MYC-tagged ubiquitin, and the cells were treated with
MG132. HA-tagged RDH12 proteins were pulled down using the
HA antibody followed by immunoblotting with MYC antibody in
order to detect the MYC-labeled ubiquitin. As shown in Fig. 4,
the formation of high molecular weight ubiquitin conjugates was
observed for all RDH12 variants, but to a very different extent.
I51N protein was more ubiquitylated than T49M while the wild-
type protein had the least number of ubiquitin residues (Fig. 4).
These results suggested that both RDH12 wild-type and mutant
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Fig. 4. Ubiquitylation assay of RDH12 variants. HEK293 cells transfected with HA-
tagged wild-type or mutant RDH12 and MYC-tagged ubiquitin expression con-
structs were incubated with (+) or without () 10 lM MG132 for 20 h. RDH12-HA
was immunoprecipitated (IP) using HA–protein A beads, and the polyubiquitin
conjugates [ub]n were detected using MYC antibodies (upper panel). Cell lysates
(20 lg) were immunoblotted (IB) with HA antibodies (middle panel), and the blot
was re-probed with b-actin antibodies (lower panel). The result is representative of
two independent experiments. Note that staining with HA antibodies shows equal
loading of RDH12 protein variants.
510 S.-A. Lee et al. / FEBS Letters 584 (2010) 507–510RDH12 proteins were targeted for degradation by the ubiquitin
conjugating system. Interestingly, the degree of polyubiquitylation
appeared to strongly correlate with the half-lives of RDH12
variants.
4. Discussion
Pulse-chase analysis carried out in this study revealed that the
primary cause of the reduced cellular levels of mutant proteins is
their accelerated degradation compared to wild-type protein. Fur-
thermore, the rates of degradation were found to be different for
the three protein forms. It has been reported that the position
and nature of the mutations inﬂuence the pathologic expression
of RDH12-linked retinal degeneration [11]. This could be due to
the differences in RDH12 variants’ catalytic efﬁciencies. However,
in the case of T49M and I51N variants, the differences in their turn-
over rates observed in this study could further modulate the dis-
ease phenotype.
Analysis of RDH12 degradation using inhibitors of speciﬁc pro-
teolytic pathways demonstrated that while lysosomes contribute
to degradation of RDH12, the major mechanism targeting RDH12
mutants for accelerated degradation appears to be through polyub-
iquitylation and subsequent destruction by the proteasome. Poly-
ubiquitylation is carried out by ubiquitin ligases located in the
cytosol. Although RDH12 is an integral membrane protein of the
endoplasmic reticulum, the majority of its polypeptide chain is
likely to be localized on the cytosolic side of the membrane as indi-
cated by the lack of glycosylation [7] and high sequence similarity
to the cytosolically-oriented RDH11 [14]. Such transmembrane
topology is consistent with the targeting of the membrane-bound
RDH12 by the cytosolic ubiquitin ligases.
Accelerated degradation of mutant proteins, provoked by aber-
rations in their conformation, is believed to represent a signiﬁcant
and prevalent pathogenic mechanism underlying genetic diseases
and was shown to occur in various subcellular compartments
[15]. A complete knockout of RDH12 gene expression in mouse
models [16,17] failed to recapitulate the phenotype observed in
human patients carrying mutations in RDH12, suggesting that
the absence of RDH12 catalytic activity alone may not be sufﬁcient
for induction of photoreceptor cell death. Perhaps replacement ofthe wild-type RDH12 gene with one of the mutant variants would
provide a more accurate model of RDH12-associated pathology
and would allow a better insight into the molecular mechanisms
of RDH12-linked retinal degeneration.
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